Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Mosenzon O, et al. Among authors: heerspink hjl. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10. Lancet Diabetes Endocrinol. 2019. PMID: 31196815 Clinical Trial.
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D. Heerspink HJ, et al. Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14. Lancet Diabetes Endocrinol. 2016. PMID: 26774608 Clinical Trial.
Unmet need in diabetic nephropathy: failed drugs or trials?
de Zeeuw D, Heerspink HJL. de Zeeuw D, et al. Among authors: heerspink hjl. Lancet Diabetes Endocrinol. 2016 Aug;4(8):638-640. doi: 10.1016/S2213-8587(16)30045-6. Epub 2016 May 6. Lancet Diabetes Endocrinol. 2016. PMID: 27160545 Review. No abstract available.
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ, de Zeeuw D, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Kohan DE, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, Sharma S, Corringham T, Sharma K, Heerspink HJL. Pena MJ, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22. Diabetes Obes Metab. 2017. PMID: 28019071 Clinical Trial.
SGLT2 inhibition: a new era in renoprotective medicine?
Muskiet MHA, Heerspink HJL, van Raalte DH. Muskiet MHA, et al. Among authors: heerspink hjl. Lancet Diabetes Endocrinol. 2017 Aug;5(8):569-571. doi: 10.1016/S2213-8587(17)30222-X. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666776 No abstract available.
430 results